Compare General Dynamics Corporation (GD) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs GSK plc — how do they compare? General Dynamics Corporation trades at $394.4 (market cap $106.03B), while GSK plc trades at $50.31 (market cap $102.60B). The key difference: General Dynamics Corporation and GSK plc are close in size by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GD | GSK | |
|---|---|---|
Market Cap | $106.03B | $102.60B |
Sector | Industrials | Health |
52-Week High | $395.97 | $61.18 |
52-Week Low | $312.53 | $38.22 |
Enterprise Value | $111.17B | $123.04B |
Dividend Yield | 1.62% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $392.68, down 0.83% on the day, amid strong fundamental performance with Q2 2026 EPS beating estimates at $4.24 versus $3.96 expected. The stock shows bullish technical signals with moving averages supporting upward momentum, while fundamentals reveal robust revenue growth to $52.55 billion in 2025 and improving profit margins. Recent contract wins including a $29.5 billion submarine award and a $1.3 billion cybersecurity contract highlight ongoing defense sector strength.
The outlook remains positive with analyst consensus pointing to 8.7% upside to the $427.40 price target, though valuation multiples appear elevated. Key risks include defense budget uncertainties and competitive pressures, while institutional sentiment remains bullish with 57% buy ratings. The company's strong backlog of $136.5 billion provides visibility for future growth.
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
